Biovie Inc (BIVI) Stock Price, Quote & News

Company Profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as fo...

Industry: Biotechnology

Sector: Healthcare

Phone: 775 888 3162

Website: bioviepharma.com

Address:

680 W. Nye Lane, Suite 204, Carson City, United States

drivinglate May. 27 at 7:47 AM

$BIVI Interesting that the long COVID bezisterim trial is fully funded by a Department of War grant.

0 · Reply

DARKP00L May. 26 at 12:32 PM

$BIVI 08:06 on May. 26 2026 BioVie Announces Full Enrollment Of ADDRESS-LC Phase 2 Trial Evaluating Drug Candidate Bezisterim For Treatment Of Neurological Symptoms Of Long COVID #tradeideas

0 · Reply

Rod75b15 May. 26 at 12:27 PM

$BIVI https://finance.yahoo.com/sectors/healthcare/articles/biovie-announces-full-enrollment-address-120000801.html

0 · Reply

Rod75b15 May. 26 at 12:14 PM

$BIVI you saw the pre-market, where for a moment it was at $1.74

0 · Reply

Rod75b15 May. 21 at 11:31 AM

$BIVI

0 · Reply

TJ12000 May. 19 at 1:26 PM

$BIVI Kong is scamming gyp

0 · Reply

Rick2058 May. 18 at 2:56 PM

$BIVI Stock Titan AI assessment of news today.

0 · Reply

BOUDIN420 May. 18 at 2:27 PM

$BIVI nice news this morning. P2 data on Deck here

0 · Reply

Rod75b15 May. 18 at 12:32 PM

$BIVI https://finance.yahoo.com/sectors/healthcare/articles/biovie-announces-completion-phase-2-120000941.html

0 · Reply

YouVSYou May. 17 at 1:35 AM

$BIVI

0 · Reply

BioVie announces full enrollment of ADDRESS-LC trial of bezisterim

May 26, 2026, 8:00 AM EDT - 23 hours ago

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

2026-05-18T12:08:40.000Z - 8 days ago

BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease

May 18, 2026, 8:00 AM EDT - 8 days ago

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease

May 11, 2026, 7:00 AM EDT - 16 days ago

BioVie Quarterly report: Q3 2026

May 7, 2026, 2:00 PM EDT - 19 days ago

BioVie Transcript: KOL event

Apr 27, 2026, 8:00 AM EDT - 4 weeks ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

Apr 16, 2026, 11:30 AM EDT - 5 weeks ago

BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 14, 2026, 8:00 AM EDT - 6 weeks ago

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

Apr 1, 2026, 7:00 AM EDT - 2 months ago

BioVie Slides: Corporate presentation

Mar 4, 2026, 4:15 PM EST - 2 months ago

BioVie Transcript: Status update

Feb 12, 2026, 12:12 PM EST - 3 months ago

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Feb 6, 2026, 7:00 AM EST - 3 months ago

BioVie Quarterly report: Q2 2026

2026-01-08T13:43:03.000Z - 4 months ago

BioVie completes enrollment in Phase 2 SUNRISE-PD trial

Dec 24, 2025, 2:05 PM EST - 5 months ago

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Nov 19, 2025, 8:00 AM EST - 6 months ago

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

Nov 10, 2025, 2:00 PM EST - 7 months ago

BioVie Transcript: AGM 2025

Nov 10, 2025, 7:00 AM EST - 7 months ago

BioVie Quarterly report: Q1 2026

Oct 8, 2025, 4:15 PM EDT - 8 months ago

BioVie Transcript: Investor Update

Sep 26, 2025, 8:00 AM EDT - 8 months ago

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

Sep 25, 2025, 8:00 AM EDT - 8 months ago

BioVie Proxy statement: Proxy Filing

2025-08-29T17:10:18.000Z - 9 months ago

BioVie price target adjusted to $12 from $6 at Brookline

Aug 15, 2025, 7:00 AM EDT - 10 months ago

BioVie Annual report: Q4 2025

Aug 13, 2025, 4:05 PM EDT - 10 months ago

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

2025-08-09T00:43:00.000Z - 10 months ago

Why Is BioVie Stock (BIVI) Down 50% Today?

2025-08-08T00:50:12.000Z - 10 months ago

BioVie 6M share Secondary priced at $2.00

Aug 7, 2025, 8:43 PM EDT - 10 months ago

BioVie Inc. Announces Pricing of $12 Million Public Offering

Aug 4, 2025, 8:00 AM EDT - 10 months ago

BioVie Registration statement: Registration Filing

2025-07-24T12:20:32.000Z - 10 months ago

BioVie presents data on Bezisterim at WCAG-2025

Jul 24, 2025, 8:00 AM EDT - 10 months ago

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

2025-07-22T12:11:30.000Z - 11 months ago

BioVie appoints Amy Chappell, Kameel Farag to board of directors

Jul 22, 2025, 8:00 AM EDT - 11 months ago

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Jul 22, 2025, 8:00 AM EDT - 11 months ago

BioVie Registration statement: Registration Filing

Jul 11, 2025, 8:00 AM EDT - 11 months ago

BioVie Registration statement: Registration Filing

2025-07-09T12:22:03.000Z - 11 months ago

BioVie reports results from bezisterim Phase 3 NM101 study

2025-07-03T20:50:10.000Z - 11 months ago

BioVie Inc. trading halted, news pending

Jul 3, 2025, 8:00 AM EDT - 11 months ago

BioVie Registration statement: Registration Filing

2025-06-26T12:16:13.000Z - 11 months ago

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

Jun 26, 2025, 8:00 AM EDT - 11 months ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Jun 24, 2025, 4:05 PM EDT - 1 year ago

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

Jun 23, 2025, 5:00 PM EDT - 1 year ago

BioVie Transcript: AGM 2025

Jun 2, 2025, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

May 28, 2025, 12:00 PM EDT - 1 year ago

BioVie Transcript: Status Update

2025-05-15T12:11:23.000Z - 1 year ago

BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

2025-05-14T11:57:58.000Z - 1 year ago

BioVie to host KOL event on Phase 2 study of bezisterim

May 14, 2025, 7:30 AM EDT - 1 year ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

May 11, 2025, 6:00 PM EDT - 1 year ago

BioVie Quarterly report: Q3 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

2025-05-07T12:24:31.000Z - 1 year ago

BioVie to present design of Phase 2 SUNRISE-PD trial

2025-05-05T12:27:31.000Z - 1 year ago

BioVie announces formation of Corporate Advisory Board

2025-04-16T12:14:13.000Z - 1 year ago

BioVie initiates SUNRISE-PD trial assessing Bezisterim

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

2025-03-19T09:00:10.000Z - 1 year ago

BioVie initiated with a Buy at Brookline

Feb 10, 2025, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q2 2025

Feb 10, 2025, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q2 2025

Nov 27, 2024, 7:00 AM EST - 1 year ago

BioVie Registration statement: Registration Filing

Nov 21, 2024, 7:00 AM EST - 1 year ago

BioVie Registration statement: Registration Filing

Nov 12, 2024, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q1 2025

Nov 7, 2024, 1:00 PM EST - 1 year ago

BioVie Transcript: AGM 2024

Oct 28, 2024, 4:10 PM EDT - 1 year ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 3:13 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 24, 2024, 4:10 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Oct 23, 2024, 3:24 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 22, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

Oct 15, 2024, 8:00 AM EDT - 1 year ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Oct 11, 2024, 9:00 AM EDT - 1 year ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

Sep 29, 2024, 6:00 PM EDT - 1 year ago

BioVie Annual report: Q4 2024

Sep 27, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

Sep 25, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Public Offering

Sep 23, 2024, 10:26 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Public Offering

Sep 23, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Proposed Public Offering

Sep 17, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

Sep 16, 2024, 8:00 AM EDT - 1 year ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 3, 2024, 8:00 AM EDT - 1 year ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Aug 27, 2024, 8:45 AM EDT - 1 year ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Aug 8, 2024, 6:00 AM EDT - 1 year ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Aug 6, 2024, 4:40 PM EDT - 1 year ago

BioVie Inc. Announces Reverse Stock Split

Jul 5, 2024, 9:00 AM EDT - 2 years ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Jun 21, 2024, 9:00 AM EDT - 2 years ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

Jun 20, 2024, 8:00 AM EDT - 2 years ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Jun 17, 2024, 8:00 AM EDT - 2 years ago

BioVie Proxy statement: Proxy Filing

Jun 12, 2024, 8:24 AM EDT - 2 years ago

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

Jun 7, 2024, 8:00 AM EDT - 2 years ago

BioVie Proxy statement: Proxy Filing

May 22, 2024, 8:00 AM EDT - 2 years ago

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

May 14, 2024, 4:00 PM EDT - 2 years ago

BioVie Quarterly report: Q3 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

drivinglate May. 27 at 7:47 AM

$BIVI Interesting that the long COVID bezisterim trial is fully funded by a Department of War grant.

0 · Reply

DARKP00L May. 26 at 12:32 PM

$BIVI 08:06 on May. 26 2026 BioVie Announces Full Enrollment Of ADDRESS-LC Phase 2 Trial Evaluating Drug Candidate Bezisterim For Treatment Of Neurological Symptoms Of Long COVID #tradeideas

0 · Reply

Rod75b15 May. 26 at 12:27 PM

$BIVI https://finance.yahoo.com/sectors/healthcare/articles/biovie-announces-full-enrollment-address-120000801.html

0 · Reply

Rod75b15 May. 26 at 12:14 PM

$BIVI you saw the pre-market, where for a moment it was at $1.74

0 · Reply

Rod75b15 May. 21 at 11:31 AM

$BIVI

0 · Reply

TJ12000 May. 19 at 1:26 PM

$BIVI Kong is scamming gyp

0 · Reply

Rick2058 May. 18 at 2:56 PM

$BIVI Stock Titan AI assessment of news today.

0 · Reply

BOUDIN420 May. 18 at 2:27 PM

$BIVI nice news this morning. P2 data on Deck here

0 · Reply

Rod75b15 May. 18 at 12:32 PM

$BIVI https://finance.yahoo.com/sectors/healthcare/articles/biovie-announces-completion-phase-2-120000941.html

0 · Reply

YouVSYou May. 17 at 1:35 AM

$BIVI

0 · Reply

Tradebait88 May. 17 at 12:09 AM

$BIVI wouldn't want to be short when data comes out

0 · Reply

BOUDIN420 May. 16 at 8:46 PM

$BIVI ww into May/June P2 readout per President/CEO in recent interview. Swing opp 🎁

0 · Reply

Rod75b15 May. 16 at 5:37 PM

$BIVI

0 · Reply

TJ12000 May. 15 at 3:17 PM

$BIVI gypsy run snake oil operation

0 · Reply

junkjar291 May. 15 at 2:33 PM

$ANVS Good news on AD enrollment but this POS is still red. $$AVXL $BIVI $SAVA all proved to be a scam, $INMB failed trial, $CGTX not sure, no plan for ph3. No other tiny company has reached this stage. Why this is red every day? Funding is a biggest problem, and no guarantee of success due to post-hoc analysis of ph2 data.

4 · Reply